Inventor
VON RAUMER MARKUS
CH20 patents
⚠️ This page may combine multiple inventors who share the name “VON RAUMER MARKUS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IDORSIA PHARMACEUTICALS LTD
13 patentsUS11680058B2Jun 20, 2023
Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
IDORSIA PHARMACEUTICALS LTD5 citations85
US10919881B2Feb 16, 2021
Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
IDORSIA PHARMACEUTICALS LTD10 citations81
US11059803B2Jul 13, 2021
Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
IDORSIA PHARMACEUTICALS LTD2 citations72
US10023560B2Jul 17, 2018
Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
IDORSIA PHARMACEUTICALS LTD3 citations72
US9914720B2Mar 13, 2018
Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
IDORSIA PHARMACEUTICALS LTD3 citations72
US9790208B2Oct 17, 2017
Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
IDORSIA PHARMACEUTICALS LTD4 citations72
US11365209B2Jun 21, 2022
Crystalline forms
IDORSIA PHARMACEUTICALS LTD1 citations70
US10730896B2Aug 4, 2020
Crystalline forms
IDORSIA PHARMACEUTICALS LTD1 citations70
US12297189B2May 13, 2025
Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
IDORSIA PHARMACEUTICALS LTD0 citations62
US11555025B2Jan 17, 2023
Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamide
IDORSIA PHARMACEUTICALS LTD0 citations62
US12534449B2Jan 27, 2026
Stable crystalline hydrate of clazosentan disodium salt
IDORSIA PHARMACEUTICALS LTD0 citations60
US11339148B2May 24, 2022
Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
IDORSIA PHARMACEUTICALS LTD0 citations51
US10351560B2Jul 16, 2019
Crystalline forms
IDORSIA PHARMACEUTICALS LTD0 citations49